Veterinary Vaccines Market to Expand at a CAGR of 5.8% during 2025-2032; Growing Awareness and Introduction of New Vaccines to Propel Market Growth

The global veterinary vaccines market size was valued at USD 12.05 billion in 2024. The market is projected to grow from USD 12.51 billion in 2025 to USD 18.56 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, “Veterinary Vaccines Market Size, Share & Industry Analysis, By Product (Inactivated, Live Attenuated, Recombinant, and Others), By Animal (Companion {Feline, Canine, Avian, and Others}, and Livestock {Poultry, Porcine, Bovine, and Others}), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, and Others), and Regional Forecast, 2025-2032”.

Veterinary vaccines refer to the dosage given to animals to protect them from infectious diseases. These vaccines are widely used to develop a protective and stronger immune system that is capable of eradicating disease-causing viruses in animals. The growing number of pet ownerships, prevalence of animal diseases, and demand for animal health protection are a few factors driving the market growth.

Introduction of New Product Portfolio by Key Players to Fuel Market Expansion

In June 2024, A well-known key player in the market, Merck Animal Health, launched a new NOBIVAC NXT Rabies product portfolio. This includes NOBIVAC NXT Canine-3 Rabies and NOBIVAC NXT Feline-3 Rabies in Canada.

Growing Awareness about Veterinary Vaccines and Launch of New Products Leads to Market Growth

The growing knowledge about veterinary healthcare and pet ownership across the globe is majorly contributing to the veterinary vaccines market growth. Additionally, there is also a rising emphasis on managing zoonotic diseases, contributing to this growth. The spread of different infections that are harmful to animals further drives the market growth. For instance, Boehringer Ingelheim International GmbH launched the VAXXITEK HVT+IBD+H5 trivalent vaccine for poultry in February 2025. This vaccine is highly used in protecting animals from different diseases, namely, Infectious Bursal Disease, Marek’s disease, and H5 avian influenza.

Conversely, lack of infrastructure availability supporting immunization for livestock in developing countries is hindering market growth.

Top Players Emphasize Providing Advanced Products to Strengthen Their Market Presence

The global market is highly competitive, with few companies conquering the market with their advanced product portfolio and key strategic decisions. A few of the prominent players in the market are Merck Animal Health, Zoetis Services LLC, and Elanco. These companies are continuously investing in research and development to gain new product approvals and expand their geographical presence.  

Notable Industry Development:

• March 2024: Researcher team from the Spanish National Council and Zendal Group have launched a vaccine capable of fighting against canine leishmaniasis.

List of the Companies Profiled in the Report:

• Elanco (U.S.)
• HIPRA (Spain)
• Boehringer Ingelheim International GmbH (Germany)
• Virbac (France)
• Merck Animal Health (U.S.)
• Zoetis Services LLC (U.S)
• Ceva (France)
• NEOGEN CORPORATION (U.S.)
• Hester Biosciences Limited (India)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/veterinary-animal-vaccines-market-101532

Further Report Findings-

• North America held the highest veterinary vaccines market share, attributed to the presence of various advanced healthcare facilities for pets. Additionally, the growing disposable income of different pet owners across the U.S. also contributed to the regional growth.
• Market growth in Asia Pacific is due to the increasing awareness of preventive measures against animal diseases. Moreover, growing government initiatives that aim at streamlining the regulations for veterinary vaccines have also contributed to the growing market demand.
• In terms of animal, the livestock segment dominated the market due to the growing need for animal-based protein and awareness about animal health. Pew owners are focusing on preventing zoonotic diseases from animals to humans, thus contributing to the segmental growth.
• Based on the route of administration, the parenteral segment leads the market, attributing to the growing steps toward inducing immunity through subcutaneous, intradermal, or intramuscular routes.

Table of Segmentation